Zimmer Biomet raised its full-year 2026 guidance after reporting second-quarter net sales of $2.177 billion, up 4.8% on a reported basis. Adjusted EPS was $2.07, unchanged from a year earlier, while U.S. organic constant-currency sales rose 4.6%. Hip sales grew 5.1% and technology, data, bone cement and surgical sales surged 21.5%, driven by strong adoption of ROSA, TMINI and OrthoGrid systems. The company now expects organic constant-currency revenue growth of 2.25% to 3.25% for 2026, up from a prior range of 1% to 3%, and raised adjusted EPS guidance to $8.47 to $8.59. Zimmer Biomet also plans up to $1 billion in share repurchases this year, $250 million above its previous expectation.
Zimmer Biomet Holdings IncRaised 2026 guidance and increased share repurchase plan
AstraZeneca PLC